The U.S. FDA rejection of an MDMA-based drug from Lykos Therapeutics for PTSD in August 2024 has not dimmed hopes that other psychedelic-oriented therapies can gain approval, according to the CEO of ...

Stimulation Clicker satirizes how it can feel to mainline the web by filling up the screen with internet videos, stock charts and Duolingo questions. There’s email to answer, too.

More than four hours before police arrived, Denise Lozano, a longtime employee of Vista-based natural soap maker Dr.

One really great thing to do every day of the week.

January 29, 2025 • Even if Greenland were for sale, buying the Artic territory would be complicated. And French President Emmanuel Macron promises to renovate the Louvre, which is falling into ...

“Ketamine in general has psychedelic properties. During the treatment, patients experience a sort of dream-like state, where they feel a little detached from reality. It is transient, and we have a ...

it's also a deep dive into the psychedelic underground; and finally, it's an art book — gorgeously illustrated, with lots of very trippy blotter art. Steve talks with Erik about the wildness of ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The ketamine-derived drug was first approved in 2019 to be used in combination with antidepressants, and later for patients experiencing suicidal thoughts or actions. “Now that it is also ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019. The spray was previously approved as a companion treatment to an oral antidepressant, as well as ...

However, medication involving the anesthetic, ketamine, has shown promise in recent years for treating these hard-to-resolve depressive symptoms. But these often rely on intravenous administration ...